Courier does not take medicine and does not perform surgery, FDA approves new technology to relieve osteoarthritis pain

▎Editor of WuXi AppTec's content team On June 9, 2021, CyMedica Orthopedics announced that the US FDA has approved a regulatory application for its IntelliHab system for the relief of knee osteoarthritis (knee osteoarthritis) pain
.

The IntelliHab system is a treatment and digital health ecosystem used at home.
It introduces a non-opioid non-invasive treatment option for patients seeking to relieve knee osteoarthritis pain, while being able to remotely provide real-time progress data to doctors
.

 Symptomatic knee osteoarthritis, also known as degenerative joint disease, not only affects the health and mobility of tens of millions of patients, but related medical expenses may cause a huge social and economic burden in the future
.

More than half of the patients are younger than 65 years old and may be affected by the disease for decades after diagnosis
.

At present, the treatment options for this disease are very limited.
The most common treatment is invasive surgery (regular injection of cortisone or hyaluronic acid, and joint reconstruction or replacement), or the use of over-the-counter painkillers and potential addiction risks Of opioids
.

The IntelliHab system relies on neuromuscular electrical stimulation therapy
.

That is, electrical impulses are directly transmitted to the motor nerves that innervate the quadriceps of the patient, so that the muscles contract in the same way as in squatting or other sports
.

These contractions can strengthen the muscles, thereby reducing the pressure on the patient's knees and achieving the effect of reducing pain
.

Patients can use the electrical stimulation system connected to the app to perform regular neuromuscular electrical stimulation at home, and manage and control their own muscle stimulation therapy through the app
.

In addition, their doctors can also remotely monitor their usage and disease progression
.

▲IntelliHab system diagram (picture source: CyMedica Orthopedics official website) FDA's 501(K) approval is based on the positive results of randomized double-blind, multi-center clinical trials
.

The trial aims to evaluate the efficacy and safety of IntelliHab in patients with knee osteoarthritis
.

The results of the test showed that the patient’s knee pain was significantly reduced and his mobility improved
.

Mr.
Rob Morocco, President and CEO of CyMedica, said: "CyMedica recognizes that there is a huge gap in the current treatment options for knee osteoarthritis pain
.

With IntelliHab obtaining regulatory approval, we can fill in conservative treatments and more invasive treatments.
The gap between treatment options allows patients to treat pain comfortably at home while reducing opioid use
.

"Reference: [1] CyMedica Orthopedics Announces FDA Clearance for IntelliHab™, a Novel Drug-free, Non-invasive Modality for Treatment of Knee Osteoarthritis Pain.
Retrieved June 9, 2021, from https:// news-releases/cymedica-orthopedics-announces-fda-clearance-for-intellihab-a-novel-drug-free-non-invasive-modality-for-treatment-of-knee-osteoarthritis-pain-301308495.
html[2] FDA clears CyMedica's app-connected muscle stimulation system to treat osteoarthritic knee pain.
Retrieved June 9, 2021, from https:// system-to-treat-osteoarthritic-knee Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.

If you need treatment plan guidance, please go to a regular hospital
.